Canaccord Genuity Keeps Their Buy Rating on Seres Therapeutics (MCRB)

Tip Ranks
2025.11.06 14:47
portai
I'm PortAI, I can summarize articles.

Canaccord Genuity analyst John Newman has reaffirmed a Buy rating on Seres Therapeutics (MCRB) with a price target of $22.00. The overall analyst consensus for Seres Therapeutics is a Moderate Buy, also with a $22.00 average price target. Newman has an average return of -1.6% and a success rate of 36.60%, covering the Healthcare sector.

Canaccord Genuity analyst John Newman maintained a Buy rating on Seres Therapeutics today and set a price target of $22.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Newman is an analyst with an average return of -1.6% and a 36.60% success rate. Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Arcellx Inc, and Regeneron.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seres Therapeutics with a $22.00 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer